Fox Chase Cancer Center News

PHILADELPHIA (March 10, 2023)—Dong “Jake” Kim, MD, a second-year hematology/oncology fellow at Fox Chase Cancer Center, recently received a 2023 Conquer Cancer Merit Award from the American Society of Clinical Oncology (ASCO) for research that he presented at a recent meeting.

PHILADELPHIA (March 2, 2023)—Fox Chase Cancer Center’s Cancer Epigenetics Institute (CEI) is holding its third annual Cancer Epigenetics Symposium at the Franklin Institute in Philadelphia today, an annual event that brings research leaders together to explore the latest discoveries, from the lab bench to the bedside, in the field.

PHILADELPHIA (February 23, 2023)—Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer, and, as the seventh leading cause of cancer death in the world, it is both aggressive and lethal.

PHILADELPHIA (February 23, 2023)—Immunotherapy—using the body’s immune system to attack cancer cells—has become a powerful cancer-fighting tool. But, for reasons that are unclear, tumors evade immune cells, making them resistant to these therapies.

PHILADELPHIA (February 22, 2023)—The Fox Chase Cancer Center Biosample Repository Facility was recently awarded accreditation from the College of American Pathologists (CAP) based on results of a recent on-site inspection.

PHILADELPHIA (February 22, 2023)—Researchers at Fox Chase Cancer Center have begun recruiting for a clinical trial called PRESERVE that will evaluate the safety and efficacy of the NanoKnife System to destroy prostate cancer cells. One of the measurements of treatment effectiveness is to assess the number of subjects that were able to avoid surgery to completely remove the prostate.

PHILADELPHIA (February 15, 2023)—John Karanicolas, PhD, co-leader of the Cancer Signaling and Microenvironment research program at Fox Chase Cancer Center, was recently awarded a $1 million grant from the W.M. Keck Foundation to develop a platform that could assist in the development of new drugs.

PHILADELPHIA (February 15, 2023)—Half of the experimental group of muscle-invasive bladder cancer patients successfully kept their bladders and reached the two-year endpoint of the RETAIN BLADDER phase II clinical trial without developing metastatic cancer, according to final results presented today by Fox Chase Cancer Center researchers at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco.